Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6879221 | 0.82 | PBRM1 (0.54) | SLC6A4SLC6A2SLC6A3HTR1ADRD1 | |
| SCHEMBL3631475 | 0.82 | ALDH1A1 (0.54) | SLC6A4HTR1AHTR6 | |
| SCHEMBL1434181 | 0.82 | F7 (0.58) | SLC6A4HTR6 | |
| SCHEMBL7461245 | 0.80 | F7 (0.65) | — | |
| SCHEMBL7461024 | 0.80 | KDM4E (0.55) | SLC6A4HTR2A | |
| SCHEMBL9937045 | 0.79 | NR4A2 (0.65) | SLC6A4 | |
| SCHEMBL26054532 | 0.79 | L3MBTL1 (0.48) | SLC6A4SLC6A2SLC6A3HTR1ADRD1 | |
| SCHEMBL12782163 | 0.77 | F7 (0.45) | SLC6A4SLC6A2SLC6A3HTR1ADRD1 | |
| SCHEMBL8808423 | 0.77 | LMNA (0.62) | SLC6A4HTR1AHTR6 | |
| SCHEMBL7386532 | 0.77 | IDO1 (0.43) | SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183252-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | AstraZeneca AB (SE) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000071537-A1 | NEW PHARMACEUTICALLY ACTIVE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |